Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Tiantan Biological ProductsSHSE:600161 -1.16%69 ROC (Joel Greenblatt) % is 8.60% as of Mar. 2026, which is 74% below its 10-year median of 32.63. GuruFocus rates SHSE:600161 with a GF Score™ of 69/100 and a GF Value™ of ¥22.93 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,322 Biotechnology companies, Beijing Tiantan Biological Products ranks better than 86.31% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Beijing Tiantan Biological Products's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.60%.
The historical rank and industry rank for Beijing Tiantan Biological Products's ROC (Joel Greenblatt) % or its related term are showing as below:
SHSE:600161'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.45 Med: 32.63 Max: 52.64
Current: 16.57
During the past 13 years, Beijing Tiantan Biological Products's highest ROC (Joel Greenblatt) % was 52.64%. The lowest was 12.45%. And the median was 32.63%.
SHSE:600161's ROC (Joel Greenblatt) % is ranked better than 86.31% of 1322
companies
in the Biotechnology industry
Industry Median: -291.605
vs SHSE:600161: 16.57
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600161 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Beijing Tiantan Biological Products's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tiantan Biological Products ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Beijing Tiantan Biological Products's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 8.60% mean?
Beijing Tiantan Biological Products (SHSE:600161) has a ROC (Joel Greenblatt) % of 8.60% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Beijing Tiantan Biological Products and its competitors. This is 74% below median its historical median of 32.63. Over the past decade, Beijing Tiantan Biological Products' ROC (Joel Greenblatt) % has ranged from 12.45 to 52.64. According to the industry distribution chart, Beijing Tiantan Biological Products ranks #181 out of 1322 companies in the Biotechnology industry, placing it in the top 13.7%.
Is Beijing Tiantan Biological Products' ROC (Joel Greenblatt) % too high?
Beijing Tiantan Biological Products' current ROC (Joel Greenblatt) % of 8.60% is 74% below median its 10-year median of 32.63. Over the past 10 years, this metric has ranged from a low of 12.45 to a high of 52.64. Based on the distribution chart, Beijing Tiantan Biological Products ranks #181 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Tiantan Biological Products has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tiantan Biological Products ranks #181 out of 1322 companies for ROC (Joel Greenblatt) %. This places Beijing Tiantan Biological Products in the top 14% of its industry — outperforming the majority of peers. Historically, Beijing Tiantan Biological Products' own ROC (Joel Greenblatt) % has ranged from 12.45 to 52.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Beijing Tiantan Biological Products and its competitors. Beijing Tiantan Biological Products's current ROC (Joel Greenblatt) % is 8.60%, which is 74% below median its own 10-year median of 32.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥22.93, compared to a current price of ¥12.78 — trading 44.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 8.60%, which is 74% below median its 10-year median of 32.63. Beijing Tiantan Biological Products' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current ROC (Joel Greenblatt) % is 8.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued.
The current stock price of ¥12.78 is trading 44.3% below its estimated GF Value™ of ¥22.93.
GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.
Key valuation signals for SHSE:600161:
ROC (Joel Greenblatt) %: 8.60% (74% below median its 10-year median of 32.63)
GF Value™: ¥22.93 vs. price of ¥12.78 (44.3% below fair value)
No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
69GF Score
Get the complete analysis for SHSE:600161
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600161 has been successfully added to your 
